Publications by authors named "Lin Taft"
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
The ASCEND-ND trial: study design and participant characteristics.
Nephrol Dial Transplant
October 2022
Article Synopsis
- Anaemia is a common issue for patients with chronic kidney disease (CKD), and it's crucial to evaluate new treatments like daprodustat compared to the existing drug, darbepoetin alfa.
- The ASCEND-ND trial involved 3,872 adult participants across 39 countries, focusing on those with specific hemoglobin levels and assessing various health characteristics related to CKD.
- The study aims to determine the effectiveness and safety of daprodustat in treating CKD-related anaemia in patients not on dialysis, providing important insights into managing this condition.
Article Synopsis
- Daprodustat, a new oral treatment for anemia in chronic kidney disease (CKD) patients not on dialysis, was compared to the standard treatment darbepoetin alfa in a phase 3 clinical trial to evaluate effectiveness and safety.* -
- The study included 3872 participants, revealing that daprodustat resulted in a slightly higher increase in hemoglobin levels (0.74 g/dL) compared to darbepoetin alfa (0.66 g/dL), meeting noninferiority benchmarks for effectiveness.* -
- Cardiovascular safety outcomes showed daprodustat was also noninferior to darbepoetin alfa, with similar rates of major adverse cardiovascular events (19.5% vs. 19
A non-parametric statistical test of null treatment effect in sub-populations.
J Biopharm Stat
March 2020
Randomized clinical trials are designed to estimate the average treatment effect (ATE). If heterogeneity of treatment effect exists, then it is possible that there may be subjects who derive a treatment effect different from the ATE. We propose a method to test the hypothesis that there exist subjects who derive benefit (or harm) against the null hypothesis that the treatment has no benefit (or harm) on each of the smallest sub-populations defined by discrete baseline covariates.
View Article and Find Full Text PDF